Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$4.85
+0.8%		$4.99
$4.59
▼
$8.31
$66.95M0.448,995 shs2,418 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
+2.56%-1.84%-9.25%-21.53%-26.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$4.85
+0.8%		$4.99
$4.59
▼
$8.31
$66.95M0.448,995 shs2,418 shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
+2.56%-1.84%-9.25%-21.53%-26.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CSBR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D)
(Data available from 10/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$59.42M1.14$0.01 per share330.67$0.29 per share16.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$1.17M-$0.08N/AN/AN/A-1.82%-25.77%-3.71%12/15/2026 (Estimated)

Latest CSBR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/10/2026Q1 2027
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$0.01$0.05+$0.06-$0.03$15.05 million$15.23 million
7/27/2026Q4 2026
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$0.05$0.01+$0.06-$0.05$12.89 million$13.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
1.03
1.03

Institutional Ownership

CompanyInstitutional Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%

Insider Ownership

CompanyInsider Ownership
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
46.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
21413.92 million7.48 millionOptionable

Recent News About These Companies

Champions Oncology Stockholders Approve Governance and Incentive Plan
October 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/champions-oncology-stockholders-approve-governance-and-incentive-plan?utm_source=marketbeat.com&utm_medium=referral
Champions Oncology (NASDAQ:CSBR) Share Price Breaks Below Two Hundred Day Moving Average - What's Next?
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31113566
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
September 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2989999/csbr-stock-slips-post-q1-earnings-despite-revenue-margin-growth?cid=cs-stocknewsapi-ft-microcap_article|earnings-2989999
Champions Oncology Reports $15.2 Million Q1 Revenue
September 11, 2026  |  ijr.comI
Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945269-champions-oncology-inc-csbr-q1-2027-earnings-call-transcript
Champions Oncology Reports Revenue of $15.2 Million
September 10, 2026  |  accessnewswire.comA
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
September 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/champions-oncology-announce-first-quarter-151500935.html
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
July 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2964901/csbr-stock-dips-post-q4-earnings-despite-record-revenue-growth-ai-push?cid=cs-stocknewsapi-ft-microcap_article|earnings-2964901
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
July 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926002-champions-oncology-inc-csbr-q4-2026-earnings-call-transcript
Champions Oncology, Inc.: Champions Oncology Reports Record Annual Revenue of $59 Million
July 27, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69136039-champions-oncology-inc-champions-oncology-reports-record-annual-revenue-of-dollar-59-million-200.htm
Champions Oncology Reports Record Annual Revenue of $59 Million
July 27, 2026  |  accessnewswire.comA
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
July 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2959626/csbr-vs-ctkb-which-life-sciences-stock-has-better-long-term-upside?cid=cs-stocknewsapi-ft-microcap_article|investment_ideas-2959626
2 Microcaps With Gross Margin Catalysts
July 23, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958775/2-microcaps-with-gross-margin-catalysts?cid=cs-stocknewsapi-ft-microcap_article-2958775
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
July 22, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2958305/zacks-initiates-coverage-of-champions-oncology-with-neutral-recommendation?cid=cs-stocknewsapi-ft-microcap_article-2958305
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
July 20, 2026  |  accessnewswire.comA
Champions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
April 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68161816-champions-oncology-inc-champions-oncology-to-present-new-data-on-predicting-response-and-resistance-at-aacr-2026-200.htm
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
April 9, 2026  |  accessnewswire.comA
Champions Oncology, Inc.: Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
March 31, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68078020-champions-oncology-inc-champions-oncology-names-brian-alexander-to-board-as-company-advances-data-driven-oncology-strategy-200.htm
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
March 30, 2026  |  accessnewswire.comA
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2026 Earnings Call Transcript
March 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/champions-oncology-inc-nasdaqcsbr-q3-2026-earnings-call-transcript-1716205/

Media Sentiment Over Time

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

$4.86 +0.06 (+1.14%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas